FLOW trial: difference between revisions
Diff·revision 4 → 5·01:26, 30 Oct 2024
Difference between revision 4 and revision 5 of FLOW trial. 2 lines changed; the page grew by 207 bytes.
| Revision 4 — 17:16, 18 Oct 2024 TirzTaxonomist (talk) split the results table so the two doses are separate rows 1,950 bytes ±0 | Revision 5 — 01:26, 30 Oct 2024 GramsNotUnitsGil (talk) label the extension study as an extension study in the table 2,157 bytes +207 | ||
|---|---|---|---|
| 11 | The primary composite comprised onset of kidney failure, a sustained fall of at least 50% in estimated glomerular filtration rate, or death from kidney or cardiovascular causes. It occurred less often on semaglutide, hazard ratio 0.76 (95% CI 0.66–0.88).{{r|perkovic2024}} | 11 | The primary composite comprised onset of kidney failure, a sustained fall of at least 50% in estimated glomerular filtration rate, or death from kidney or cardiovascular causes. It occurred less often on semaglutide, hazard ratio 0.76 (95% CI 0.66–0.88).{{r|perkovic2024}} |
| 12 | 12 | ||
| + | 13 | The trial is significant because its endpoints are hard rather than surrogate: kidney failure and sustained loss of filtration function, not albuminuria alone. See [[Surrogate endpoint]].{{r|perkovic2024}} | |
| + | 14 | ||
| 13 | == Design == | 15 | == Design == |
| 14 | Participants had type 2 diabetes with an estimated glomerular filtration rate and albumin-to-creatinine ratio within defined ranges, and were on maximum tolerated renin–angiotensin system blockade. The trial therefore tested semaglutide added to established renal protection rather than in its place.{{r|perkovic2024}} | 16 | Participants had type 2 diabetes with an estimated glomerular filtration rate and albumin-to-creatinine ratio within defined ranges, and were on maximum tolerated renin–angiotensin system blockade. The trial therefore tested semaglutide added to established renal protection rather than in its place.{{r|perkovic2024}} |